Epigenetic biomarkers for smoking cessation.
Epigenetic biomarkers for smoking cessation.
复制标题
DOI：
10.1016/j.addicn.2023.100079
复制
发表时间：
2023-06-01
期刊：
影响因子：
--
通讯作者：
Hancock, Dana B
中科院分区：
文献类型：
--
作者：
Fang, Fang;Andersen, Allan M;Hancock, Dana B
吸烟与表观遗传改变有关，这种改变在戒烟后可能是可逆的。作为研究最多的表观遗传修饰，DNA甲基化与吸烟暴露密切相关，提供了一种潜在的机制，将吸烟与不利的健康后果联系起来。在这里，我们回顾了可接触的外周组织(主要是血液)中DNA甲基化与戒烟相关的可逆性，以及DNA甲基化作为区分当前吸烟者、既往吸烟者和从不吸烟者以及量化戒烟以来时间的生物标记物的用途。我们从候选基因和表观基因组范围的关联研究中总结了数千个差异甲基化胞嘧啶鸟嘌呤(CpG)二核苷酸和与戒烟相关的区域，以及多CpG预测吸烟状态的准确性。总体而言，有强有力的证据表明DNA甲基化是戒烟的标志。然而，仍有空白需要填补，包括(1)在测量血液DNA甲基化方面的细胞类型异质性；(2)非欧洲血统人群的代表性不足；(3)用于定量测量戒烟后随时间推移的DNA甲基化的纵向数据有限；以及(4)研究戒烟对其他表观遗传特征、非编码RNA和组蛋白修饰的影响的数据有限。表观遗传学机制提供了有前景的生物标志物，可以在临床环境中提高戒烟的成功率。为了实现这一目标，更大和更多样化的样本以及更广泛的表观遗传标记的纵向测量将是开发强大的DNA甲基化生物标记分析的关键，然后在将其作为临床有用的工具实施之前满足对该分析的验证要求。
Cigarette smoking has been associated with epigenetic alterations that may be reversible upon cessation. As the most-studied epigenetic modification, DNA methylation is strongly associated with smoking exposure, providing a potential mechanism that links smoking to adverse health outcomes. Here, we reviewed the reversibility of DNA methylation in accessible peripheral tissues, mainly blood, in relation to cigarette smoking cessation and the utility of DNA methylation as a biomarker signature to differentiate current, former, and never smokers and to quantify time since cessation. We summarized thousands of differentially methylated Cytosine-Guanine (CpG) dinucleotides and regions associated with smoking cessation from candidate gene and epigenome-wide association studies, as well as the prediction accuracy of the multi-CpG predictors for smoking status. Overall, there is robust evidence for DNA methylation signature of cigarette smoking cessation. However, there are still gaps to fill, including (1) cell-type heterogeneity in measuring blood DNA methylation; (2) underrepresentation of non-European ancestry populations; (3) limited longitudinal data to quantitatively measure DNA methylation after smoking cessation over time; and (4) limited data to study the impact of smoking cessation on other epigenetic features, noncoding RNAs, and histone modifications. Epigenetic machinery provides promising biomarkers that can improve success in smoking cessation in the clinical setting. To achieve this goal, larger and more-diverse samples with longitudinal measures of a broader spectrum of epigenetic marks will be essential to developing a robust DNA methylation biomarker assay, followed by meeting validation requirements for the assay before being implemented as a clinically useful tool.